The Journal of Gene Medicine

Cover image for Vol. 17 Issue 1-2

Edited By: Shigetaka Asano, Olivier Danos, Kay Davies, Pierre Lehn, Richard Mulligan

Impact Factor: 1.953

ISI Journal Citation Reports © Ranking: 2013: 73/124 (Medicine Research & Experimental); 86/165 (Biotechnology & Applied Microbiology); 112/165 (Genetics & Heredity)

Online ISSN: 1521-2254

Author Guidelines

Permission Request Form

For additional tools visit Author Resources - an enhanced suite of online tools for Wiley-Blackwell journal authors, featuring Article Tracking, E-mail Publication Alerts and Customized Research Tools.

Author Guidelines

The Journal of Gene Medicine is committed to rapid publication of articles. It is the intention of the Editorial Office to peer review manuscripts and notify authors of the decision within four weeks. Upon acceptance, the full text is published online in 'Accepted Articles' in within eight weeks of acceptance and subsequently appears in the next available print issue.

Initial manuscript submission

The Journal of Gene Medicine operates an online submission, peer-review and manuscript tracking system. All papers must be submitted via this online system. Details of how to submit online and full author instructions can be found at
Preferred file formats for text and tables are .doc or .rtf. Figures should be .tiff or .eps.

Submission is considered on the conditions that papers are previously unpublished, and are not offered simultaneously elsewhere; that all authors have read and approved the content, and all authors have also declared all competing interests; and that the work complies with Ethical Policies of the journal, and has been conducted under internationally accepted ethical standards after relevant ethical review. It is highly recommended you read this policy and complete any necessary documentation prior to your submission

A manuscript may be returned to the authors without outside review if it is deemed to be outside the scope of the journal, or if it fails to meet key criteria imposed by the journal, these being to be adequately novel; to advance the field sufficiently; or to be satisfactorily controlled. This decision will be made at the Editors' discretion.

Revised manuscripts should be submitted within three months of receiving the Editors’ decision, using the ‘create a revision’ option for the initial manuscript. They should also include a point-by-point letter specifying how the author has responded to the reviewers’ and Editors’ comments.

For all submission enquiries please contact the editorial office - Email:

Review articles are typically by invitation only, but proposals may be accepted after editorial approval. Please contact the Editorial Office with your proposal before submitting a review article.

The Journal also publishes Letters to the Editor, and Responses to a Letter from the authors of original articles that are commented upon in Letters that are accepted for publication. These should be kept brief, and be written in clear and balanced language, to allow healthy scientific discourse to take place.

Final accepted manuscripts

Upon acceptance, authors will be asked to submit the following to the Production Editor:

  • any required permission letters - it is the author's responsibility to obtain written permission to reproduce (in all media) any material which has appeared in another publication

Manuscript style
  • All submissions must have a title page with the full title, a short title (no more than 40 characters, spaces included) and names and affiliations of all authors. Give the full address, including email, telephone and fax of the corresponding author.
  • Supply an abstract of up to 250 words. An abstract is a concise summary of the whole article, not just the conclusions, and is understandable without reference to the rest of the article. It should contain no citation to other published work. For original research papers, divide the abstract into four short paragraphs labelled: Background, Methods, Results, Conclusions.
  • Include up to six keywords that describe your paper for indexing purposes.
  • Original research papers should be structured into headed sections as follows: Title, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, Conflicts of Interest Statement, References. Other subsection headings within the main headings may be used, but these should be limited.
  • The Acknowledgements section must include the name(s) of any sponsor(s) of the research contained in the paper, along with grant number(s).
  • Abbreviations are not encouraged except for units of measurement and universally recognized abbreviations (e.g. DNA). When an abbreviation appears in the text for the first time, it should be placed in parentheses after the words for which it stands.

The Editor reserves the right to alter manuscripts whenever necessary to make them conform to the stylistic and bibliographical conventions of the Journal.

Materials and Methods

Research reports should include all information and raw data necessary to allow others to replicate the experiments and results described. Authors are strongly encouraged to share any novel reagents that are not commercially available with other researchers. Generic names should be used for all compounds, trade names may be used in parentheses after the generic name. The sources of unusual materials and chemicals, and the manufacturer and model of equipment used should be indicated. Authors are also encouraged to consult and follow any reporting guidelines relevant to their specific research design, in particular:

Research Ethics

A statement of ethics committee or institutional review board approval of the studies being reported must be made in the Materials and Methods section and the relevant reference numbers and dates must be given.
When reporting experiments on human subjects, indicate whether procedures were in accordance with the ethical standards of the institutional, regional, or national committee on human experimentation, and with the Helsinki Declaration of 1975, as revised in 1983. Patients’ rights to privacy must not be infringed without informed consent. Do not use patients’ names, initials, hospital numbers or any other identifying information in any part of a manuscript (text or figures), unless the information is essential for scientific reasons and the patient (or their parent or guardian) has given written informed consent for publication.
When reporting experiments on animals, indicate whether the institution’s or a national research council’s guide for, or any national law on, the care and use of laboratory animals was followed. We ask all authors to carefully consider the ethical use of animals in their research.

Conflicts of interest statement

Authors are responsible for disclosing all financial and personal relationships between themselves (or close relatives) and other parties (such as commercial companies) that might bias their work. A conflict of interest statement must be included in every manuscript and it must detail any conflicts that exist for each author, or declare the absence of conflict for each author. Potential conflicts include, but are not limited to: employment, membership upon an Advisory Board, receiving grants to cover research, travel or accommodation, the ownership of shares, share options, stocks or bonds, being named on a related patent, being loaned or given equipment, etc.


References should be cited by bracketed numbers and listed at the end of the paper in the order in which they appear in the text. All references must be complete and accurate. For articles with more than 6 authors, only the first 3 authors should be listed, followed by et al. For articles with 6 authors or fewer, all names should be listed. Where possible the DOI for the reference should be included at the end of the reference. Online citations should include date of access. Use Medline abbreviations for journal names, which can be found at: If necessary, cite unpublished or personal work in the text but do not include it in the reference list. References should be listed in the following style:

  • Rosenberg S, Aebersold P, Cornetta K, et al. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using TIL modified by retroviral gene transduction. N Engl J Med 1990; 323: 570-578.DOI: 10.1002/nej.850
  • Kemshead J, Patel K. N-myc - Its place as a diagnostic and prognostic indicator in neuroblastoma. In Genes and Cancer, Sikora K, Carney D (eds). John Wiley & Sons: Chichester, 1990; 145-157.
  • Lowenstein PR, Enquist LW (eds). Transfer in Neuroscience: Towards Gene Therapy of Neurological Disorders. John Wiley & Sons: New York, 1996.


Submit each illustration as a separate file except compound figures e.g. 1a, 1b, 1c etc, which should be supplied as a single file. Type each table on a separate page with a brief title. Supply artwork at the intended size for printing. Line drawings are acceptable as clear black on white graphics and must be high quality. Use hatchings, not tints. Figures should be supplied (uploaded) as tiff files in RGB or greyscale mode with no profile embedded and no layers. All illustrations must be supplied at the correct resolution:

  • Black and white and colour photos – 300dpi.
  • Graphs, drawings, etc – 800dpi preferred; 600dpi minimum.
  • Combinations of photos and drawings (black and white and colour) – 500dpi.

Before submitting your files online please ensure that you have named the individual files appropriately, taking care to include the number of any figure in the filename.

Supporting Information

Wiley Blackwell is able to host online additional files of supporting information that authors submit with their paper. These files must be important, ancillary information that is relevant to the article but which does not or cannot appear in the printed edition of the Journal. Authors should consult our guidelines for preparing supporting information for further information, including a list of accepted file types.

If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper. The corresponding author MUST submit the CTA as it is a requirement for publication.

For authors signing the copyright transfer agreement
If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:

CTA Terms and Conditions

For authors choosing OnlineOpen
If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution License OAA
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services and visit

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit:

Accepted Articles
Peer reviewed articles that have been accepted for publication in The Journal of Gene Medicine are now rapidly published online before being copy-edited and typeset. The articles are published on the Accepted Articles page of the journal website, as PDFs, with a *DOI (digital object identifier), so they can be cited. Subsequently, the full copy-edited and typeset articles will appear in an online issue, after proofing by the authors.

Readers should note that the versions of articles published within Accepted Articles should not be considered the version of record. Wiley-Blackwell cannot be held responsible for errors or consequences arising from the use of information contained in these articles.

*The Digital Object Identifier (DOI) is an identification system for intellectual property in the digital environment. Developed by the International DOI Foundation on behalf of the publishing industry, its goals are to provide a framework for managing intellectual content, link customers with publishers, facilitate electronic commerce, and enable automated copyright management.

Authority and Responsibility
The intellectual content of the paper is the responsibility of the authors. The Editors and the Publisher accept no responsibility for opinions and statements of authors. While every effort will be made by the Editor and Publisher to avoid inaccurate and misleading data, they accept no liability whatsoever for the consequences of wrong information. The authors agree to keep the Editors and Publisher fully and effectually indemnified against any liability or claims that may arise out of the publication of inaccurate and/or misleading data.

Note to NIH and HHMI Grantees

Wiley Blackwell will automatically deposit the accepted (not edited and typeset) version of primary research papers funded by these bodies to PubMedCentral. For NIH authors the papers are made freely available twelve months after acceptance and for HHMI authors six months after acceptance, for more details see our full policy statements:

Further Information

Proofs will be sent to the corresponding author for checking. This stage is to be used only to correct errors that may have been introduced during the production process. Prompt return of the corrected proofs, preferably within 2 days of receipt, will minimise the risk of the paper being held over to a later issue. Free access to the final PDF offprint or your article will be available via Author Services. Please therefore sign up for Author Services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers.